AIN 457

Known as: AIN-457, AIN457 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
01220102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the… (More)
Is this relevant?
2016
2016
We have previously demonstrated that interleukin-17A (IL-17) producing T helper 17 cells are significantly elevated in blood and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Anti-cytokine autoantibodies have been widely reported to be present in human plasma, both in healthy subjects and in patients… (More)
Is this relevant?
Review
2013
Review
2013
The most significant data presented at the 28th Congress of the European Committee for Treatment and Research in Multiple… (More)
Is this relevant?
2012
2012
To the Editor: The articles by Papp and col­ leagues1 and Leonardi and colleagues2 (both in the March 29 issue) attest to the… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Interleukin-17A (IL-17A) is elaborated by the T helper 17 (T(H)17) subset of T(H) cells and exhibits potent proinflammatory… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2010
2010
monoclonal antibody AIN457, which is being developed by Novartis, has shown promising efficacy for the treatment of psoriasis… (More)
Is this relevant?